The emergence of mephedrone as well as other synthetic cathinones has introduced problems for lawmakers and regulatory companies tasked with managing the proliferation of latest psychoactive substances. The dynamic character of synthetic drug creation, coupled with the power of chemists to switch molecular constructions to evade legal restrictions,